# OnCo record tnbc-immunomodulatory (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/tnbc-immunomodulatory/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "tnbc-immunomodulatory" ;
  schema:name "Immunomodulatory triple-negative breast cancer (IM)"@en ;
  schema:alternateName "IM subtype"@en, "Immunomodulatory TNBC"@en, "Basal-like immune-activated (BLIA, Burstein)"@en ;
  schema:description "Immunomodulatory triple-negative breast cancers are the ones packed with immune cells. The 2016 re-analysis showed the signature comes from those lymphocytes rather than the tumour, so today the same idea is captured by counting tumour-infiltrating lymphocytes on the biopsy, which predicts a better outcome and is used to test whether some small tumours need less treatment."@en ;
  schema:url <https://onco.cc/cancers/tnbc-immunomodulatory/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tumor-infiltrating_lymphocytes> ;
  schema:citation <https://doi.org/10.1172/jci45014>, <https://doi.org/10.1371/journal.pone.0157368>, <https://doi.org/10.1158/1078-0432.ccr-14-0432>, <https://doi.org/10.1056/nejmoa2202809> ;
  onco:tag "breast", "tnbc", "subtype-page" ;
  onco:related <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-mesenchymal-stem-like/>, <https://onco.cc/cancers/tnbc-basal-like-1/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/pd1/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/tils/>, <https://onco.cc/terms/pd-l1-cps-10-tnbc/>, <https://onco.cc/terms/cps/> ;
  onco:trials <https://onco.cc/trials/keynote-355/> ;
  onco:standardOfCare <https://onco.cc/trials/keynote-355/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/terms/cps/>, <https://onco.cc/terms/pd-l1-cps-10-tnbc/> .